Mar 20,2017

Click Therapeutics Presents Data on Increased Efficacy of a Digital Therapeutics Program for Smoking Cessation at Six-Month Mark of Clinical Trial

Click Therapeutics announced highlights from a poster presentation at the Annual Meeting of the Society for Research on Nicotine and Tobacco on the recently completed clinical trial of Clickotine®, a Digital Therapeutics program for smoking cessation and the company’s first commercially available product on its platform. These data were from the 6-month post-enrollment follow-up of an 8-week, single-arm clinical trial of Clickotine as a treatment for smoking cessation. All study procedures were IRB approved; data were collected in Amazon S3 with no manual data entry, and access to all data was maximally restrictive, logged and auditable.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Mar 31,2017

One Drop demonstrates improvements in A1c

One Drop today announced findings from a retrospective study demonstrating that One Drop | Mobile app users report a substantial improvement in glycemic control, reducing A1c by 1.0 percentage point after only 2 to 12 months of using One Drop | Mobile. Data was presented yesterday at the 38th Annual Meeting & Scientific Sessions of the Society of Behavioral Medicine in San Diego.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 25,2017

Click Therapeutics Announces Multiple Publications of Clinical Data Supporting Digital Therapeutics™ Programs for Smoking Cessation and Major Depressive Disorder

Click Therapeutics announces today multiple publications of research data supporting its digital therapeutics for smoking cessation and major depressive disorder. The results of a 416-person clinical trial of Clickotine, a digital therapeutic for smoking cessation, have been published in JMIR mHealth and uHealth. This trial found Clickotine to be engaging for users (100.6 app opens on average), as well as efficacious. Interim efficacy results of Click’s novel cognitive-emotional digital therapeutic for major depressive disorder show that compared to an active control group, Click’s intervention resulted in significantly greater MDD symptom reduction after the 6-week regimen (42.9% compared to 15.7% in the control group).

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
May 21,2017

Feasibility and Clinical Impact of Deploying a Digital Health Intervention on a Medicare Population with Asthma or Chronic Obstructive Pulmonary Disease (COPD)

Digital health interventions have demonstrated positive impacts on clinical outcomes in asthma, but data on their impact in chronic obstructive pulmonary disease (COPD), and among older populations, have been limited. Research aimed to assess the feasibility and clinical impact of a digital health intervention in a Medicare population with COPD or asthma. 236 participants were enrolled, including 198 with COPD and 38 with asthma. Of these participants, 222 (94%) synced a sensor to begin data transmission and 192 (81%) were active after 10 months.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 14,2016

Effectiveness of Population Health Management Using the Propeller Health Asthma Platform: A Randomized Clinical Trial

Telemonitoring of short-acting b-agonist (SABA) focuses on patterns of use and may allow more timely action to avert exacerbations. Studies assessing this approach are lacking. This pragmatic controlled study was designed to measure real-world effectiveness of the Propeller Health Asthma Platform to reduce use of SABA and improve asthma control. A total of 495 patients were enrolled in parallel arms (1:1) for 12 months of monitoring SABA use. Intervention group (IG) patients received access to and feedback from the Propeller Health system. Routine care (RC) patients were outfitted with sensors but did not receive feedback. Compared with RC, the study arm monitoring SABA use with the Propeller Health system significantly decreased SABA use and improved Asthma Control Test-ACT scores

CLINICAL STUDY

#telehealth

#connected device

View Analyst & Ambassador Comments
Go to original news
Feb 18,2016

ATENTIVmynd™ Games Lead to Significant and Sustained Reductions in Core Symptoms of Attention Deficit Hyperactivity Disorder and Improved Academic Performance

Attention Therapeutics LLC, a wholly owned subsidiary of Atentiv LLC and developer of digital health products, announced the results of a randomized, controlled and parallel human phase II clinical trial, which demonstrated that a novel nonpharmacological intervention, ATENTIVmynd™ Game training, resulted in significant and sustained reduction in the core symptoms of Attention Deficit/Hyperactivity Disorder (ADHD) in children aged 8-12, along with significant improvement in academic performance. Improvements from the ATENTIVmynd™ Game were sustained at follow-up three months later

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Aug 24,2016

The Largest And Longest Study Of Patients With Schizophrenia Interacting With Digital Therapeutics Results Released

Pear Therapeutics (PEAR), the creator of prescription digital therapies called eFormulations, announced today results from a real-world implementation study examining a research version of THRIVE, PEAR’s digital therapy for treating patients with Serious Mental Illness including schizophrenia, schizoaffective disorder, and bipolar disorder. The study evaluated 342 participants between 18-60 years of age, who had been diagnosed with a psychotic disorder and were discharged from a psychiatric hospitalization within 60 days. Seventy-four percent (73.6%) of patients were successfully able to use the digital therapy 3-6 months after discharge, and on average, participants used the digital therapy for 82% of the weeks they had a mobile phone.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 21,2016

Click Therapeutics Reports Preliminary Results of a Clinical Study on Engagement and Efficacy of Clickotine

Click Therapeutics, Inc. announces today preliminary results of its fully remote clinical trial of Clickotine, a digital program designed for smoking cessation. The study was conducted to investigate the feasibility of a fully digital clinical trial, to validate the engagement of the CLICK Neurobehavioral Intervention (CNI) Platform, and to explore the efficacy of Clickotine for smoking cessation. Primary outcome of the study was user-engagement, with additional outcomes measuring smoking behavior and safety. 45.2% of participants (n=188) had stopped smoking at the end of the study; 26.2% of participants (n=109) achieved 30-day sustained abstinence after 8 weeks.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 21,2016

Patient Reported Value and Usability of a Digital Health Intervention for Asthma

Digital health tools are increasingly recognized as effective in improving asthma clinical outcomes such as control and adherence; however, few studies have evaluated patient perspectives on the usability and value of these tools in supporting asthma self-management. The sudy aimed to assess patients’ usability feedback and satisfaction with an asthma digital health platform after 12 months of use. Research administered surveys to participants of a randomized controlled clinical study designed to measure the clinical effectiveness of the Propeller Health Asthma Platform.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 13,2015

Study Shows Omada Health’s Online DPP Participants Maintained Reductions in Weight and Average Blood Sugar Levels

According to a study published Friday in the peer-reviewed Journal of Medical Internet Research (JMIR), participants in Omada Health’s online diabetes prevention program Prevent maintained reductions in body weight and average blood sugar levels across a two-year horizon. Becoming the first digital health company to publish two-year, peer-reviewed outcomes, Omada Health programs continue to demonstrate best-in-class clinical results for using intensive behavioral counseling to spur and maintain lifestyle changes. Prevent participants also demonstrated higher rates of program completion, and continued to engage with Prevent after the 12-month curriculum concluded.

CLINICAL STUDY

#coaching

#cbt

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY